Hansa Biopharma AB (STO:HNSA), a provider of immunomodulatory enzyme technology for rare IgG-mediated diseases, announced on Thursday that it has appointed Donato Spota as new chief financial officer of the company, effective 15 May 2019.

Eva-Maria Joed, currently serving as CFO, will continue in the company as VP, Finance & Administration, reporting to Spota.

Spota, a senior executive with more than 20 years of international pharmaceutical industry experience, most recently was with Basilea Pharmaceutica AG for 16 years, where he served as CFO for the past five years.

Prior to that, he held other senior financial leadership positions, including global head of Finance & Services and head of Global Controlling. Before that, Spota held senior positions in financial planning and controlling at F. Hoffmann-La Roche for six years in Basel, Switzerland.